SpliceBio — Series A · €50M

SpliceBio raised an oversubscribed €50M Series A for its protein-splicing platform, which uses engineered inteins from Princeton's Muir Lab to deliver genes too large for a single AAV vector; its lead programme targets Stargardt disease. UCB Ventures and Ysios Capital co-led, so no single lead is stated.

LeadUCB Ventures, Ysios Capital RoundSeries A Announced16 Feb 2022 CityBarcelona SectorHealthtech & Bio · Biotech / gene therapy Source W

Something wrong? Suggest a correction →